LAB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LAB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Standard BioTools's Cost of Goods Sold for the three months ended in Dec. 2023 was $14.8 Mil. Standard BioTools's Average Total Inventories for the quarter that ended in Dec. 2023 was $21.2 Mil. Standard BioTools's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.70.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Standard BioTools's Days Inventory for the three months ended in Dec. 2023 was 130.62.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Standard BioTools's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.75.
The historical data trend for Standard BioTools's Inventory Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard BioTools Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Inventory Turnover | Get a 7-Day Free Trial | 3.94 | 3.27 | 3.02 | 2.88 | 2.66 |
Standard BioTools Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Inventory Turnover | Get a 7-Day Free Trial | 0.73 | 0.59 | 0.63 | 0.65 | 0.70 |
Standard BioTools's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as
Inventory Turnover (A: Dec. 2023 ) | |||||||
= | Cost of Goods Sold | / | Average Total Inventories | ||||
= | Cost of Goods Sold (A: Dec. 2023 ) | / ( | (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) |
= | 55.89 | / ( | (21.473 | + | 20.533) | / | 2 ) |
= | 55.89 | / | 21.003 | ||||
= | 2.66 |
Standard BioTools's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as
Inventory Turnover (Q: Dec. 2023 ) | |||||||
= | Cost of Goods Sold | / | Average Total Inventories | ||||
= | Cost of Goods Sold (Q: Dec. 2023 ) | / ( | (Total Inventories (Q: Sep. 2023 ) | + | Total Inventories (Q: Dec. 2023 )) | / | count ) |
= | 14.831 | / ( | (21.927 | + | 20.533) | / | 2 ) |
= | 14.831 | / | 21.23 | ||||
= | 0.70 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard BioTools (NAS:LAB) Inventory Turnover Explanation
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Standard BioTools's Days Inventory for the three months ended in Dec. 2023 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Dec. 2023 ) | / | Cost of Goods Sold (Q: Dec. 2023 ) | * | Days in Period |
= | 21.23 | / | 14.831 | * | 365 / 4 | |
= | 130.62 |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Standard BioTools's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Dec. 2023 ) | / | Revenue (Q: Dec. 2023 ) |
= | 21.23 | / | 28.188 | |
= | 0.75 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.
Thank you for viewing the detailed overview of Standard BioTools's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Martin D Madaus | director | 290 CONCORD ROAD, BILLERICA MA 01821 |
Jeffrey G. Black | officer: SVP & Chief Financial Officer | 4955 DIRECTORS PLACE, SAN DIEGO CA 92121 |
Eli Casdin | director, 10 percent owner | 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019 |
Casdin Partners Master Fund, L.p. | director, 10 percent owner | WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001 |
Casdin Partners Fo1-msv, Lp | director | C/O CASDIN PARTNERS GP, LLC, 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019 |
Casdin Private Growth Equity Fund Ii Gp, Llc | director | 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019 |
Casdin Partners Gp, Llc | director, 10 percent owner | 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019 |
Casdin Capital, Llc | director, 10 percent owner | 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019 |
Casdin Private Growth Equity Fund Ii, L.p. | director | 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019 |
Fenel M Eloi | director | C/O INTERLEUKIN GENETICS INC, 135 BEAVER STREET, WALTHAM MA 02452 |
Caligan Partners Lp | 10 percent owner | 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022 |
Frank Witney | director | 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451 |
Jeremy Steven Davis | officer: SVP Chief Commercial Officer | C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080 |
Hanjoon Alex Kim | officer: Chief Operating Officer | C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080 |
Michael Egholm | director, officer: President & CEO | 1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110 |
From GuruFocus
By GlobeNewswire GlobeNewswire • 04-20-2023
By PRNewswire • 10-04-2023
By PRNewswire • 12-26-2023
By Marketwired • 11-02-2023
By PRNewswire • 12-28-2023
By Business Wire • 10-06-2023
By sperokesalga sperokesalga • 05-25-2023
By GlobeNewswire • 12-23-2023
By Business Wire • 12-05-2023
By sperokesalga sperokesalga • 04-20-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.